Byetta lawsuit filings, along with dozens of claims alleging pancreatic injuries caused by other medications part of a class of drugs known as incretin mimetics have been consolidated in the Southern District of California, according to recent court documents.

The newly-established federal proceeding for Byetta and Januvia lawsuits, which include claims of pancreatitis, pancreatic cancer and thyroid cancer stemming from the type-2 diabetes drugs, was created via a Transfer Order issued on August 26th by the U.S. Judicial Panel on Multidistrict Litigation. Court documents indicate that more than 53 cases alleging injuries from Byetta, Januvia and other incretin mimetics had been filed in jurisdictions throughout the U.S. prior to consolidation. Given the rising concerns about the pancreatic side effects associated with Byetta, the number of cases filed in this federal proceeding now underway in the U.S. District Court, Southern District of California is likely to rise in the coming months.

Byetta Lawsuit Claims Follow FDA Warning about Incretin Mimetics

Not to mention the U.S. Food and Drug Administration (FDA)’s recently announced investigation of Byetta and pancreatic side effects. An alert published March 14, 2013 indicated that the agency was made aware of an unpublished study that lent evidence to the possibility that use of incretin mimetics may cause pancreatic duct metaplasia, which is classified as pre-cancerous cellular changes in the pancreas.

A month after this warning was issued, the Institute for Safe Medicine Practices reported in April 2013 that patients taking Byetta or another medications may be 25 times more likely to develop pancreatic cancer than one who did not. The group’s analysis of the FDA database of adverse event reports revealed that Byetta had been named in 263 counts of pancreatitis, 71 reports of pancreatic cancer and 14 cases of thyroid cancer. This information was taken over a 12 year period ending in June 2012. A study published in the British Medical Journal on June 10th stated the makers of incretin mimetics may have downplayed the pancreatic side effects associated with their products.

Federally-filed Januvia and Byetta lawsuits allege their manufacturers failed to warn doctors and patients about the medications’ potential to cause pancreatitis, pancreatic cancer and possibly thyroid cancer.

Start the Process of Filing a Byetta Lawsuit

If you took Byetta or another incretin mimetic to treat type-2 diabetes, the time is now to state your case against the manufacturer of the medication that harmed you. Contact the lawyers at Bernstein Liebhard LLP to start the process of filing a claim at (877) 779-1414.

Published August 28, 2013 by